Skip to main navigation Skip to search Skip to main content

Somatic SETBP1 mutations in myeloid malignancies

  • Hideki Makishima
  • , Kenichi Yoshida
  • , Nhu Nguyen
  • , Bartlomiej Przychodzen
  • , Masashi Sanada
  • , Yusuke Okuno
  • , Kwok Peng Ng
  • , Kristbjorn O. Gudmundsson
  • , Bandana A. Vishwakarma
  • , Andres Jerez
  • , Ines Gomez Segui
  • , Mariko Takahashi
  • , Yuichi Shiraishi
  • , Yasunobu Nagata
  • , Kathryn Guinta
  • , Hiraku Mori
  • , Mikkael A. Sekeres
  • , Kenichi Chiba
  • , Hiroko Tanaka
  • , Hideki Muramatsu
  • Hirotoshi Sakaguchi, Ronald L. Paquette, Michael A. McDevitt, Seiji Kojima, Yogen Saunthararajah, Satoru Miyano, Lee Yung Shih, Yang Du, Seishi Ogawa, Jaroslaw P. Maciejewski*
*Corresponding author for this work
  • Cleveland Clinic Foundation
  • The University of Tokyo
  • Uniformed Services University of the Health Sciences
  • Kyoto University
  • Nagoya University
  • Showa Medical University
  • University of California at Los Angeles
  • Johns Hopkins University
  • Chang Gung Memorial Hospital

Research output: Contribution to journalJournal Article peer-review

233 Scopus citations

Abstract

Here we report whole-exome sequencing of individuals with various myeloid malignancies and identify recurrent somatic mutations in SETBP1, consistent with a recent report on atypical chronic myeloid leukemia (aCML). Closely positioned somatic SETBP1 mutations encoding changes in Asp868, Ser869, Gly870, Ile871 and Asp880, which match germline mutations in Schinzel-Giedion syndrome (SGS), were detected in 17% of secondary acute myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases. These results from deep sequencing demonstrate a higher mutational detection rate than reported with conventional sequencing methodology. Mutant cases were associated with advanced age and monosomy 7/deletion 7q (-7/del(7q)) constituting poor prognostic factors. Analysis of serially collected samples indicated that SETBP1 mutations were acquired during leukemic evolution. Transduction with mutant Setbp1 led to the immortalization of mouse myeloid progenitors that showed enhanced proliferative capacity compared to cells transduced with wild-type Setbp1. Somatic mutations of SETBP1 seem to cause gain of function, are associated with myeloid leukemic transformation and convey poor prognosis in myelodysplastic syndromes (MDS) and CMML.

Original languageEnglish
Pages (from-to)942-946
Number of pages5
JournalNature Genetics
Volume45
Issue number8
DOIs
StatePublished - 08 2013
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Somatic SETBP1 mutations in myeloid malignancies'. Together they form a unique fingerprint.

Cite this